Your Location：Home >Products >API >184475-35-2
pd_meltingpoint:119-120 °C
Appearance:light-yellow crystalline powder
Purity:99%
Factory Supply Industrial Grade Gefitinib 184475-35-2 with Best Price We supply high quality Gefitinib (CAS 184475-35-2), in stock, factory directly supply to clients, lower prices, more competitiveness.
Gefitinib is light-yellow crystalline powder, while it's Molecular Formula is C22H24ClFN4O3. Gefitinib has been used : To study its effective use in endometrial cancer therapy Cell proliferation, cell cycle and apoptosis assays Cell viability assay and colony formation assay
The CAS number of Gefitinib is 184475-35-2.
More information of Gefitinib 184475-35-2 are:
|
Synonyms |
N-(3-chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine;ZD1839;4-(3-Chloro-4-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline;Irressat;Gefitinib (JAN/USAN);4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-;ZD 1839;4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-; |
|
CAS Number |
184475-35-2 |
|
Molecular Formula |
C22H24ClFN4O3 |
|
Molecular Weight |
446.909 |
|
Density |
1.322 g/cm3 |
|
Melting Point |
119-120 °C |
|
Boiling Point |
586.8 °C at 760 mmHg |
|
Flash Point |
308.7 °C |
|
HS CODE |
29349990 |
|
PSA |
68.74000 |
|
LogP |
4.28650 |
|
Pka |
7.00±0.10(Predicted) |
Gefitinib was introduced in Japan as a daily oral monotherapy for the treatment of inoperable or recurrent non-small cell lung cancers (NSCLC). This anilinoquinazoline derivative can be synthesized in 6 steps starting from 6,7-dimethoxyquinazolin-4(3H)-one by successive monodemethylationlacetylation of the 6-hydroxy-group followed by chlorination and reaction with 3-chloro-4-fluoroaniline, finally deacetylation and alkylation with 3-(4-morpholinyl)propylbromide complete the synthesis. Gefitinib reversibly inhibits the activity of the epidermal growth factor receptor tyrosine kinase (EGRF TK). This inhibits autophosphorylation of EGRF and blocks the cascade of intracellular events which have been implicated in the proliferation, survival and metastasis of cancer cells. Gefitinib diplays good selectivity for the EGRF TK relative to other growth factors in human umbilical endothelial cells. It is similarly selective relative to other kinases, for example cerB2. Data from two large phase II studies in patients with pretreated NSCLC have shown that gefitinib induces a response rate approaching 20% in patients receiving the agent as a second line therapy and approximately 10% in those pretreated with more lines of chemotherapy. Gefitinib has good bioavailability and is metabolized in the liver via the cytochrome P450 3A4 enzyme system with a mean elimination half life of 28 h. Gefitinib has been generally well tolerated in cancer patients with predominant side effects being acne-like skin-rash, diarrhea, nausea, vomiting and mild to moderate myelosuppression. .
InChI:InChI=1/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)
Articles related to Gefitinib:
|
Article |
Source |
|
Novel preparation of gefitinib |
Zheng, Youguang,Li, Mingdong,Zhang, Shaoning,Ji, Min , p. 388 - 390 (2009) |
|
Improved protocol for synthesis of N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy) quinazolin-4-amine (gefitinib) |
Kumar, Pawan,Mazlee, Muhammad Taufiq F.,Abdul Wahab, Muhammad K.,Belwal, Chandra Kant,Kumar, Ramesh,Sajid, Shahnawaz , p. 39 - 46 (2019) |
Zibo Yurui Biotechnology Co., Ltd is a quality supplier and manufacturer of Gefitinib . You can buy high quality, low price Gefitinib 184475-35-2 here. Contact us.
CAS：850140-73-7
CAS：122111-03-9
CAS：874819-74-6
CAS：1035979-44-2
